ScreenerHero

VRTX Vertex Pharmaceuticals Incorporated

NAS · US · Healthcare · Biotechnology · vrtx.com
502.31USD-0.24%Mkt Cap: 127.24B $P/E: 29.26

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on spec…

Industry Peers

Biotechnology
Screen all
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD
BBIO
BridgeBio Pharma, Inc.
$13.09BUSD

Key Statistics

Company
Market Cap127.24B USD
Enterprise Value122.05B USD
Revenue (TTM)12.59B USD
Gross Profit10.35B USD
Net Income (TTM)3.95B USD
Revenue/Share49.51 USD
Last Price502.31 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees6.4K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)29.26
P/E (Forward)25.10
PEG1.97
EV/EBITDA23.93
EV/Revenue9.70
P/S10.16
P/B6.32
EPS (TTM)17.17
EPS (Forward)20.11
52W Range
374.1769% of range560.25
52W High560.25 USD
52W Low374.17 USD
Profitability
Gross Margin86.24%
Oper. Margin38.05%
EBITDA Margin40.52%
Profit Margin32.94%
ROE21.18%
ROA15.42%
Growth
Revenue Growth12.50%
Earnings Growth8.00%
Cash Flow & Leverage
Operating CF3.63B USD
CapEx (TTM)437.60M USD
FCF Margin20.88%
FCF Yield2.07%
Net Debt-5.87B USD
Net Debt/EBITDA-1.15
Balance Sheet
Debt/Equity0.11
Current Ratio3.19
Quick Ratio2.54
Book Value/Sh79.92 USD
Cash/Share30.98 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateAug 24, 2000
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)571.39 USD
Upside (mean)+13.8%
Target Range350.00 USD – 672.00 USD
350.00+13.8% to mean672.00
# Analysts28
Ownership
Shares Out.253.30M
Float252.69M
Insiders0.21%
Institutions97.95%
Short Interest
Short Ratio4.7d
Short % Float2.10%
Short % Out.1.86%
Shares Short4.72M
Short (prev mo.)4.15M
Technical
SMA 50518.20 (-3.1%)
SMA 200473.62 (+6.1%)
Beta0.32
S&P 52W Chg14.58%
Avg Vol (30d)1.00M
Avg Vol (10d)999.62K
Technical Indicators
RSI (14)39.9
MACD-2.7167
MACD Signal0.6631
MACD Hist.-3.3798
BB Upper547.60 USD
BB Middle519.98 USD
BB Lower492.36 USD
BB Width10.62%
ATR (14)12.21 USD
Vol Ratio (20d)0.75x